Wednesday, 7 September 2016

Cell Phone-Enabled Diagnostics Market Analysis, Trends 2015 to 2023

Most of the low to medium income, developing nations are many times deprived of medical and other healthcare facilities, due to several reasons such as distance between the patient and healthcare service providers and others. Researchers have devised an important solution to this by creating medical diagnostic applications that are really small and can fit into the objects that people are already using in their day to day life. Cell phones were identified as one such object that can bring the hospital to the door or in the hand of the patient. Some of the emerging cell phone-enabled diagnostics include, cell-phone lensfree microscope, cell-phone based imaging using microchip ELISA, mobile phone based clinical microscopy, cell-phone based platform as a biomedical device and telemedicine tools using mobile phone cameras along with paper microfluidics. Some of the examples of these cell phone-based diagnostic tests applications are Roche's Accu-ChekA Glucose Buddy, which is an iPhone application and Arkray's Smart e-SMBG, which is an android application. Tests for sexually transmitted diseases and many other infectious diseases are in huge demand worldwide, which are in their developmental stages at different universities and companies. The cell phone-enabled diagnostics market can be classified into five major segments, namely, cell phone-enabled diagnostics for diabetes, cell phone-enabled rapid immunoassays, cell-phone enabled microscopy, and cell phone-enabled molecular tests.

Download Complete Healthcare Analytical Brochure:

Major driving factors for the growth of this market include, technological advancements in diagnostic testing techniques, increasing number of applications of cell phone-based diagnostics, and rising awareness and demand for various cell phone-based technologies. Recent technological advancements have made researchers to think and develop cell phone-based applications that can help in different diagnostic tests. At present, cell phone based diagnostic tests are available for diabetes, histology, hematology, immunoassays and others, which will help grow this market. Rising number of applications of these cell phone-based diagnostics will further boost this market’s growth. Major objective of developing these cell phone-based diagnostics was to reach the underserved population of the world that is mainly located in low to medium income, developing nations. Thus, increasing awareness about such applications along with increasing trend of using smartphones will create more demand for such diagnostics; in turn will contribute towards the growth of this market. However, the cell phone-based diagnostics is still at its nascent stage both in developed as well as developing economies. Future growth will depend both on smartphone industry as well as type of applications for different diagnostic tests installed and utilized by its users worldwide.

Geographically, North America dominates the cell phone-based diagnostics market with highest market share followed by the European market. Major factors responsible for the growth of this market in these regions are high awareness and demand for advanced and point of care diagnostics, high usage of smartphones as well as smartphone based applications in these regions and early availability of newly launched diagnostic applications in these regions. However, other emerging nations located in regions like Asia-Pacific, LATAM and Middle East are expected to grow at a fast pace in near future due to increasing number of smartphone users in most of the developing regions and huge unmet needs of the population present in these regions. Ease of use as well as easy reach in rural areas of these regions of cell phone-based diagnostics will also drive this market’s growth in future. Some of the major players operating in this market are AgaMatrix, Inc., Alere, Inc., ARUP Laboratories, BIO-key International, Inc., CellScope, Inc., Genomic Health, Inc., GenPrime, Inc., GlySens Incorporated, HolGenTech, Inc., Leica Microsystems, Lifescan, Inc., Medtronic, Inc., Oasis Scientific, Inc., QIAGEN and TelCare, Inc.

Browse Research Report on Global Cell Phone-Enabled Diagnostics Market:

Wednesday, 31 August 2016

Global Asthma and COPD Drug Market a CAGR figure of 1.03% by 2017

According to the new report published by Transparency Market Research "Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017", the global asthma and COPD market was worth USD 25,102.3 million in 2010, which is expected to reach USD 26,965.5 million in 2017 along with a CAGR figure of 1.03% over the forecasted period (2010 - 2017). 

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. In 2010, the asthma drug segment dominated the overall asthma and COPD market at USD 14,509.1 million. In the same year, the COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.
In medical parlance, asthma is defined as a respiratory condition wherein, the airways through which a body breathes becomes inflamed and constricted due to one or more environmental triggers. This condition is considered to be a serious disorder in a human body and over 300 million people suffer from asthma in the world. Asthma is often treated with drug therapy and by avoiding any type of triggers. The total drug market for asthma is worth over $15 billion. 

For several decades, pharmaceutical companies have created more effective asthma products and faster acting drugs to treat asthma. The latest generation of asthma drugs such as GlaxoSmithKline's Advair and AstraZeneca's Symbicort are now poised to take over the older products in the market. GlaxoSmithKline, AstraZeneca and Merck will continue to be the market leaders until their patents expire in the forthcoming years. However, Symbicort, Advair and Singulair would still remain to be the leading drugs of the global asthma and COPD market for the forecast period 2010 – 2017. Advair was seen as the market leader to treat asthma with USD 7,802 million in 2011, followed by Singulair which was the second largest drug in terms of revenue at UD 5479 million in 2011. 

Also, due to the rising demand of new entrants in combinational therapies, beta-agonists, and inhaled corticosteroids, the extreme competition in the asthma market is becoming popular and intense now-a-days. The opportunities are growing in the asthma and COPD market as huge companies are focusing on contract manufacturing outsourcing (CMO) and key market players are involved into developing new products to treat asthma better. 

This research report is specially designed to analyze and estimate the market demand, performance and size of the overall Asthma and COPD Market in a global scenario. Along with the historical data and forecasts, the report also includes the market size, in-depth analysis of value chain, product sales, production forecasts and various other key factors driving and restraining this market. One of the most noticeable factors driving this market is – the increase in awareness about the regular diagnosis for Asthma and COPD, and availing the healthcare equipment for the detection of illness and disorder in the rural areas. Such factors will likely boost the market and growth opportunities for market players across the world. 

The recent years has showed China as one of the top ranking countries in occurrence of asthma patients. The factors affecting it are air pollution, growth in urbanization, increased smoking activities, and change in lifestyle. The occurrence of asthma symptoms is higher in the urban China towns as compared to the rural areas.  

Browse Research Report on Global Asthma and COPD Drug Market:

Nanotechnology Drug Delivery Market to Exhibit 12.5% CAGR during 2015-2023 due to Growing Demand for Effective Drug Delivery in Cancer Patients

Transparency Market Research has published a new market research report titled, “Nanotechnology Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.” According to the report, the global nanotechnology drug delivery market was valued at US$ 4.1 Bn in 2014 and is estimated to reach US$ 11.9 Bn in 2023, expanding at a CAGR of 12.5% from 2015 to 2023.

Application of nanotechnology is aimed at improving drug delivery. Advancement in nanotechnology has revolutionized the delivery of nanometer range of drug molecules. Rising prevalence of infectious diseases and cancer, significant nanotechnology research, and increasing demand for novel drug delivery systems are driving the nanotechnology market. However, unspecific regulatory guidelines for novel nanotechnology based drugs is expected to hamper market growth during the forecast period. The global nanotechnology drug delivery market was valued at US$ 4.1 Bn in 2014 and is anticipated to reach US$ 11.9 Bn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023. 

Nanoparticles dominated the global nanotechnology drug delivery market in 2014 due to wide range of applications and increase in demand for nanoparticles globally. The dendrimers sub-segment dominated the nanoparticles segment owing to factors such as polyvalency, flexibility in size and shape, monodispersity, biocompatibility, and better transfection properties than other technologies. However, the nanotubes segment is expected to expand at the highest growth rate during the forecast period. Growth of this segment is attributed to high efficiency of nanotubes in health care specifically in drug delivery, bio-sensing methods for disease treatment, and health monitoring. 

Oncology was the largest application segment of the nanotechnology drug delivery market in terms of revenue in 2014. The segment is expected to dominate the market during the forecast period. Rise in demand for effective treatment therapies for cancer coupled with increasing incidence of this disease drives the oncology application segment. Neurology was the second largest application segment of the nanotechnology drug delivery market in 2014 due to efficient application of nanotechnology in neuromolecular diagnostics and discovery of neurodegenerative markers. 

The cardiovascular application segment is expected to expand at the highest CAGR during the forecast period from 2015 to 2023. Most of the research studies related to nanotechnology-based cardiovascular treatment drugs are in pipeline; however, groundbreaking innovation in this field is expected to drive this market. 

The global nanotechnology drug delivery market is consolidated, with relatively small number of companies accounting for majority of the market share in 2014. AbbVie, Inc., Amgen, Inc., Johnson & Johnson, Novartis AG, and Teva Pharmaceutical Industries Ltd. are the key players in the global nanotechnology drug delivery market. 

Browse Research Report on Global Nanotechnology Drug Delivery Market

Tuesday, 30 August 2016

Leading Producers of MDD, Anxiety, and Panic Disorder Therapeutics Focusing on Novel Drugs Post Recent Patent Expiries, Says TMR

The increasing prevalence of various psychological problems such as stress and sleeplessness is boosting the demand for MDD, anxiety, and panic disorder therapeutics. In its report, titled “MDD, Anxiety and Panic Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” Transparency Market Research (TMR) studies the various factors impacting the market’s trajectory. 

Download Exclusive Global Strategic Business Report:

Recent patent expiries did create a few bottlenecks for the market, but key players are investing in the research and development to discover novel therapeutics. Presently, cognitive-behavioral therapy (CBT) is an effective treatment for psychological disorder but it requires the support of anti-depressants in the first line of treatment, apart from other drugs. However, administering anti-depressants could trigger panic attacks in patients with bipolar disorders, which can be analyzed by mapping the patient’s family history before diagnosis. 

Lack of awareness about comparable theories could prove damaging for the market. Hence, the leading producers of MDD, anxiety, and panic disorder therapeutics have been finding it difficult to penetrate underdeveloped regions as they lack adequate support of skilled medical professionals. Nevertheless, opportunities across developing and underdeveloped economies are expected to rise as their governments plan to accelerate healthcare spending. 

Based on recent updates, TMR forecasts promising growth for the global MDD, anxiety, and panic disorder market. The forthcoming patent expiry of blockbuster drugs such as Eli Lilly’s Cymbalta and BMS/Otsuka’s Abilify is likely to create growth opportunities for market players. Besides this, the key market players are also looking to gain from pipeline products such as Alkermes and Forest (Actavis)/Gedeon’s ALKS-5461, Naurex’s GLYX-13, and Richter/Mitsubishi Tanabe Pharma’s cariprazine. Approval of these pipeline drugs will fuel sales prospects in the market. 

Epidemiologic studies have found that a majority of individuals experiencing panic attacks are likely to experience MDD at some point. This factor boosts the chances of the co-occurrence of panic disorders. These disorders can lead to functional disability along with triggering suicidal instincts in patients. Be it the current hectic lifestyle or a prolonged family history of anxiety, the world today is witnessing more cases of MDD, anxiety, and panic disorders than ever before. This would accelerate the demand for effective diagnosis and treatment modalities to help patients not succumb to the condition. 

TMR therefore forecasts that the demand for novel therapeutics will surge in response to the rising incidence of anxiety, panic disorders, and MDD. Some of the key players in the global MDD, anxiety, and panic disorder market likely to gain from the prevailing trends are Forest Laboratories, Shire Plc, Astra Zeneca Plc, Novartis AG, Eli Lilly and Company, BTG International (BTG), Janssen Pharmaceuticals, Inc. (JPI), Pfizer, Inc., H. Lundbeck A/S, and Alexza Pharmaceuticals. 

Browse Research Report on Global MDD, Anxiety and Panic Disorder Therapeutics Market:

Monday, 29 August 2016

Availability of Cheaper Treatment Options Drives Global Medical Tourism Market

A market study on the global tourism market, recently published by Transparency Market Research (TMR) estimates this market to rise at an exceptional CAGR of 17.90% over the period from 2013 to 2019 and reach a value US$32.5 bn by the end of the forecast period.The research report, titled “Medical Tourism Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” states that the worldwide medical tourism market attained a value of US$10.5 bn in 2012.

Download Free exclusive Sample of this report:
Medical tourism is defined as traveling from one location to another with a purpose to gain medical assistance. Generally, people from developing nations travel to developed countries for medical treatments that are unavailable in their own countries due to poor medical and healthcare infrastructure. However, in recent years, people residing in developed economies have also begun travelling to lesser developed countries in order to gain cost-efficient medical assistance.

According to this study, the falling cost of medical procedures in the Philippines, India, Singapore, Thailand, Mexico, Malaysia, Brazil, Turkey, Taiwan, South Korea, Poland, Costa Rica, and Dubai is encouraging people to travel to these countries for their treatment and, in turn, is propelling the global medical tourism market significantly.

In addition, the widening range of medical treatments available in these nations, coupled with technical advancements in the field of medical and healthcare, is likely to boost this market greatly during the forecast period, states the market report.

In this study, the global medical tourism market is analyzed on the basis of its regional spread. India, Singapore, Thailand, Malaysia, Brazil, Mexico, Turkey, Taiwan, and South Korea are the major medical tourism markets across the world.

Thailand has emerged as the most popular destination for cosmetic surgeries among the medical tourists from Western Europe. In 2012, this country had welcomed around 2.5 million foreign patients, accounting for approximately 45% of the overall number of foreign medical tourists arrived in Asia. However, Malaysia is likely to dominate the global medical tourism market in the coming years.

Almost 0.7 million patients were treated in this nation in 2012. Analysts expect around 2 mn patients to gain medical assistance in Malaysia by the end of the forecast period, notes the research report.

The report further states that India and Singapore are the most preferred destinations in case of complex medical procedures. India has attracted a large number of patients due to its increasing popularity in the field of cardiac treatments. Costa Rica, Dubai, Poland, and the Philippines have been identified as the prospective countries for medical tourism in this market study.

Samitivej Sukhumvit, Raffles Medical Group, Fortis Healthcare Ltd., Apollo Hospitals Enterprise Ltd., Bangkok Hospital Medical Center, Asian Heart Institute, Bumrungrad International Hospital, KPJ Healthcare Berhad, Min-Sheng General Hospital, and Prince Court Medical Center are some of the major organizations operating in the global medical tourism market.

Browse Research Report on Global Medical Tourism Market: